{"id":252,"date":"2020-06-01T09:47:15","date_gmt":"2020-06-01T09:47:15","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=252"},"modified":"2020-06-01T09:47:15","modified_gmt":"2020-06-01T09:47:15","slug":"01-june-2020-interferon-beta-66-7-discharge-rate-in-ifn-group-on-day-14-compared-to-43-6-in-control-group","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/01-june-2020-interferon-beta-66-7-discharge-rate-in-ifn-group-on-day-14-compared-to-43-6-in-control-group\/","title":{"rendered":"(01 June 2020) Interferon beta- 66.7% discharge rate in IFN group on day 14 compared to 43.6% in control group"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.28.20116467v1<\/p>\n<p class=\"\">In this randomized clinical trial (Clinical Trial Registration ID #IRCT20100228003449N28)efficacy and safety of IFN \u03b2-1a has been evaluated in patients with severe COVID-19.&nbsp; Forty-two patients in the interferon group received IFN beta-1a in addition to the standard of care. Each 44 micrograms\/ml (12 million IU\/ml) of interferon beta-1a was subcutaneously injected three times weekly for two consecutive weeks. The control group received only the standard of care.&nbsp; As primary outcome, time to the clinical response was not significantly different between the IFN and the control groups (9.7 +\/- 5.8 vs. 8.3 +\/- 4.9 days respectively, P=0.95). On day 14, 66.7% vs. 43.6% of patients in the IFN group and the control group were discharged, respectively (OR= 2.5; 95% CI: 1.05- 6.37). The 28-day overall mortality was significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p= 0.015). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118). Although did not change time to reach the clinical response, adding to the standard of care significantly increased discharge rate on day 14 and decreased 28-day mortality.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.28.20116467v1 In this randomized clinical trial (Clinical Trial Registration ID #IRCT20100228003449N28)efficacy and safety of IFN \u03b2-1a has been evaluated in patients with severe COVID-19.&nbsp; Forty-two&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/01-june-2020-interferon-beta-66-7-discharge-rate-in-ifn-group-on-day-14-compared-to-43-6-in-control-group\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(01 June 2020) Interferon beta- 66.7% discharge rate in IFN group on day 14 compared to 43.6% in control group&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,30],"tags":[63],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/252"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=252"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/252\/revisions"}],"predecessor-version":[{"id":253,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/252\/revisions\/253"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}